Literature DB >> 15303502

Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer.

Marianne Nordsmark1, Jens Overgaard.   

Abstract

There is evidence that tumor hypoxia adversely affects loco-regional tumor control and survival in head and neck cancer. The aim of the current study was to compare pretreatment tumor oxygenation measured by Eppendorf pO2 electrodes with known prognostic factors in advanced head and neck tumors after definitive radiotherapy, and to evaluate the prognostic significance of these parameters on loco-regional tumor control. Sixty-seven patients, median age 56 years (22-82), all with primary stage III-IV squamous cell carcinoma were available for survival analysis. Tumor oxygenation was described as the fraction of pO2 values < or = 2.5 mmHg (HP2.5) and the median tumor pO2. By regression analysis HP2.5 was independent of known prognostic factors including stage, pretreatment hemoglobin (Hb) and the largest tumor diameter at the site of pO2 measurement. By Kaplan-Meier analysis loco-regional tumor control at 5 years was in favor of less hypoxic tumors using either HP2.5 or median tumor pO2 as descriptors and stratifying by the median values. Also, Hb was prognostic of loco-regional tumor control at 5 years using the median value as cut off. HP2.5 as continuous parameter was highly significant for loco-regional tumor control in a multivariate analysis. In conclusion both HP2.5 and total Hb were prognostic for loco-regional tumor control, but HP2.5 as continuous variable was independently the strongest prognostic indicator for loco-regional tumor control after definitive primary radiotherapy in advanced head and neck tumors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15303502     DOI: 10.1080/02841860410026189

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  43 in total

1.  DLK1, delta-like 1 homolog (Drosophila), regulates tumor cell differentiation in vivo.

Authors:  Asma Begum; Yuri Kim; Qun Lin; Zhong Yun
Journal:  Cancer Lett       Date:  2011-12-03       Impact factor: 8.679

2.  Monte Carlo radiotherapy simulations of accelerated repopulation and reoxygenation for hypoxic head and neck cancer.

Authors:  W M Harriss-Phillips; E Bezak; E K Yeoh
Journal:  Br J Radiol       Date:  2011-10       Impact factor: 3.039

3.  FDG-PET, a Complementary Modality to Computed-Tomography in Radiotherapy Target Volume Delineation for Head and Neck Cancer.

Authors:  Voichita Bar-Ad; Wenyin Shi; Madalina Tuluc; Nitin Ohri; David Cognetti; Joseph Curry; Charles Intenso
Journal:  J Nucl Med Radiat Ther       Date:  2012-02-01

Review 4.  Hypoxia gene expression signatures as predictive biomarkers for personalising radiotherapy.

Authors:  Lingjian Yang; Catharine Ml West
Journal:  Br J Radiol       Date:  2018-03-20       Impact factor: 3.039

Review 5.  Imaging tumor hypoxia to advance radiation oncology.

Authors:  Chen-Ting Lee; Mary-Keara Boss; Mark W Dewhirst
Journal:  Antioxid Redox Signal       Date:  2014-03-24       Impact factor: 8.401

6.  The anti-protozoan drug nifurtimox preferentially inhibits clonogenic tumor cells under hypoxic conditions.

Authors:  Quhuan Li; Qun Lin; Hoon Kim; Zhong Yun
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

Review 7.  Hypoxic tumor microenvironment and cancer cell differentiation.

Authors:  Yuri Kim; Qun Lin; Peter M Glazer; Zhong Yun
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

8.  Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma.

Authors:  Yong Qin; Jason Roszik; Chandrani Chattopadhyay; Yuuri Hashimoto; Chengwen Liu; Zachary A Cooper; Jennifer A Wargo; Patrick Hwu; Suhendan Ekmekcioglu; Elizabeth A Grimm
Journal:  Mol Cancer Ther       Date:  2016-07-25       Impact factor: 6.261

9.  Tissue oxygenation in a murine SCC VII tumor after X-ray irradiation as determined by EPR spectroscopy.

Authors:  Hirotada Fujii; Koh-Ichi Sakata; Yoshihiro Katsumata; Rikiya Sato; Makoto Kinouchi; Masanori Someya; Shin-Ichiro Masunaga; Masato Hareyama; Harold M Swartz; Hiroshi Hirata
Journal:  Radiother Oncol       Date:  2008-02-20       Impact factor: 6.280

10.  Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer.

Authors:  Gillian Thomas; Shamshad Ali; Frank J P Hoebers; Kathleen M Darcy; William H Rodgers; Malti Patel; Ovardia Abulafia; Joseph A Lucci; Adrian C Begg
Journal:  Gynecol Oncol       Date:  2007-11-26       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.